Clare Arnott's Publications

About Clare Arnott's Publications

Global Director, Cardiovascular Program
  • Co-Director, Global Chronic & Complex Diseases
  • BMed Sci,
  • MBBS (Hons),
  • PhD,
  • FRACP,
  • FESC,
  • CF

  • The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program

    International Journal of Cardiology Date published:

  • Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes

    Diabetes, Obesity and Metabolism Date published:

  • Sodium-glucose co-transporter-2 inhibition and ocular outcomes in patients with type 2 diabetes: A systematic review and meta-analysis

    Diabetes, Obesity and Metabolism Date published:

  • Blood pressure postpartum (BP2) RCT protocol: Follow-up and lifestyle behaviour change strategies in the first 12 months after hypertensive pregnancy

    Pregnancy Hypertension Date published:

  • Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes

    Kidney International Date published:

  • Prognostic Value of Secreted Frizzled-Related Protein 5 in Heart Failure Patients With and Without Type 2 Diabetes Mellitus

    Circulation: Heart Failure Date published:

  • Rationale, design, and baseline characteristics of the Salt Substitute in India Study (SSiIS): The protocol for a double-blinded, randomized-controlled trial

    The Journal of Clinical Hypertension Date published:

  • Comparative Efficacy and Safety of BP-Lowering Pharmacotherapy in Patients Undergoing Maintenance Dialysis

    Clinical Journal of the American Society of Nephrology Date published:

  • The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trial

    Diabetes, Obesity and Metabolism Date published:

  • 27-OR: Effect of Canagliflozin on Total Hospitalization for Heart Failure Events in Patients with Type 2 Diabetes and Chronic Kidney Disease

    Diabetes Date published:

  • 1130-P: Mediators of the Effects of Canagliflozin (CANA) on Heart Failure (HF) and CV Death in Patients with Type 2 Diabetes (T2D) and Chronic Kidney Disease (CKD)

    Diabetes Date published:

  • P1028EFFECTS OF CANAGLIFLOZIN ON MAJOR ADVERSE CARDIOVASCULAR OUTCOMES IN PATIENTS WITH DIFFERENT BASELINE LEVELS OF TYPE 2 DIABETES MELLITUS DISEASE SEVERITY: RESULTS FROM THE CANVAS PROGRAM

    Nephrology Dialysis Transplantation Date published:

  • Maternal cardiovascular risk after hypertensive disorder of pregnancy

    Heart Date published:

  • Prognosis of unrecognised myocardial infarction determined by electrocardiography or cardiac magnetic resonance imaging: systematic review and meta-analysis

    BMJ Date published:

  • Elastic Chest Compression Reduced Hyperinflation in People with Chronic Obstructive Pulmonary Disease

    D28. COPD: FROM PATHOGENESIS TO PROGNOSIS Date published:

  • Women and Cardiovascular Disease: Pregnancy, the Forgotten Risk Factor

    Heart, Lung and Circulation Date published: